Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, Schöffski P, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Shi K, Ruiz-Soto R, George S, von Mehren M

Open source

DOI
10.1016/s1470-2045(20)30168-6
Published
2020 Jul
Container
The Lancet. Oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-20-30168-6,
  title = {Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.},
  author = {Blay JY and Serrano C and Heinrich MC and Zalcberg J and Bauer S and Gelderblom H and Schöffski P and Jones RL and Attia S and D'Amato G and Chi P and Reichardt P and Meade J and Shi K and Ruiz-Soto R and George S and von Mehren M},
  year = {2020},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(20)30168-6},
  url = {https://doi.org/10.1016/s1470-2045(20)30168-6}
}

RIS

TY  - JOUR
TI  - Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
AU  - Blay JY
AU  - Serrano C
AU  - Heinrich MC
AU  - Zalcberg J
AU  - Bauer S
AU  - Gelderblom H
AU  - Schöffski P
AU  - Jones RL
AU  - Attia S
AU  - D'Amato G
AU  - Chi P
AU  - Reichardt P
AU  - Meade J
AU  - Shi K
AU  - Ruiz-Soto R
AU  - George S
AU  - von Mehren M
PY  - 2020
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(20)30168-6
UR  - https://doi.org/10.1016/s1470-2045(20)30168-6
ER  - 

APA

JY, B., C, S., MC, H., J, Z., S, B., H, G., P, S., RL, J., S, A., G, D., P, C., P, R., J, M., K, S., R, R., S, G., & M, V. M. (2020). Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(20)30168-6

Source records